Education
About Us
Working with TipRanks
Follow Us
Irhythm Technologies (IRTC)
NASDAQ:IRTC
IRTC Stock Chart & Stats
$123.59
-$0.21(-0.23%)
At close: 4:00 PM EST
$123.59
-$0.21(-0.23%)
Day’s Range― - ―
52-Week Range$92.52 - $212.00
Previous CloseN/A
Volume94.23K
Average Volume (3M)727.24K
Market Cap
$3.99B
Enterprise Value$4.49B
Total Cash (Recent Filing)$583.76M
Total Debt (Recent Filing)$731.18M
Price to Earnings (P/E)―
Beta0.80
Next Earnings
Apr 30, 2026EPS Estimate
-0.67Next Dividend Ex-DateN/A
Dividend YieldN/A
Share Statistics
EPS (TTM)0.17
Shares Outstanding32,316,760
10 Day Avg. Volume919,668
30 Day Avg. Volume727,240
Financial Highlights & Ratios
PEG Ratio2.07
Price to Book (P/B)37.18
Price to Sales (P/S)7.60
P/FCF Ratio164.50
Enterprise Value/Market Cap1.12
Enterprise Value/Revenue6.01
Enterprise Value/Gross Profit8.51
Enterprise Value/Ebitda-570.49
Forecast
1Y Price Target
$213.00Price Target Upside72.34% Upside
Rating ConsensusStrong Buy
Number of Analyst Covering12
EPS Forecast (FY)-0.36
Revenue Forecast (FY)$874.98M
Bulls Say, Bears Say
Bulls Say
Medicare Advantage Market OpportunityChanges to Medicare Advantage rules that favor auditable clinical documentation could expand reimbursement and patient access, supporting increased uptake of Zio monitoring solutions.
Product Demand And AdoptionZio AT's faster-than-average growth alongside robust Zio Monitor unit sales signals accelerating customer adoption that can materially boost revenue.
Profitability And Cash GenerationAchievement of positive GAAP earnings per share and free cash-flow generation indicates improving profitability and provides greater financial flexibility for reinvestment and growth initiatives.
Bears Say
Guidance And Valuation PressureCompany guidance falling short of analyst expectations, combined with valuation multiple compression among peers, can weaken investor confidence and apply downward pressure on the stock.
Product Launch Timing RiskDelay in the commercial launch of the Zio MCT product reduces near-term revenue visibility and may postpone expected contributions from the new offering.
Regulatory And Legal RiskAn additional civil investigative demand focused on Zio AT reimbursement claims increases the risk of regulatory enforcement actions, potential repayments, or compliance-related costs.
Irhythm Technologies News
IRTC FAQ
What was Irhythm Technologies’s price range in the past 12 months?
Irhythm Technologies lowest stock price was $92.52 and its highest was $212.00 in the past 12 months.
What is Irhythm Technologies’s market cap?
Irhythm Technologies’s market cap is $3.99B.
When is Irhythm Technologies’s upcoming earnings report date?
Irhythm Technologies’s upcoming earnings report date is Apr 30, 2026 which is in 53 days.
How were Irhythm Technologies’s earnings last quarter?
Irhythm Technologies released its earnings results on Feb 19, 2026. The company reported $0.17 earnings per share for the quarter, beating the consensus estimate of $0.011 by $0.159.
Is Irhythm Technologies overvalued?
According to Wall Street analysts Irhythm Technologies’s price is currently Undervalued.
Does Irhythm Technologies pay dividends?
Irhythm Technologies does not currently pay dividends.
What is Irhythm Technologies’s EPS estimate?
Irhythm Technologies’s EPS estimate is -0.67.
How many shares outstanding does Irhythm Technologies have?
Irhythm Technologies has 32,316,760 shares outstanding.
What happened to Irhythm Technologies’s price movement after its last earnings report?
Irhythm Technologies reported an EPS of $0.17 in its last earnings report, beating expectations of $0.011. Following the earnings report the stock price went down -4.985%.
Which hedge fund is a major shareholder of Irhythm Technologies?
Currently, no hedge funds are holding shares in IRTC
What is the TipRanks Smart Score and how is it calculated?
Smart Score combines eight research factors - such as analyst recommendations, hedge fund trends, and technical indicators - to measure a stock’s outlook. These signals are unified into a single score that reflects bullish or bearish momentum. See detailed methodology
Irhythm Technologies Stock Smart Score
Underperform
1
2
3
4
5
6
7
8
9
10
Analyst Consensus
Strong Buy
Average Price Target:
$213.00 (72.34% Upside)
$213.00 (72.34% Upside)
Blogger Sentiment
Bullish
IRTC Sentiment 100%
Sector Average ―
Sector Average ―
Hedge Fund Trend
Decreased
By 480.2K Shares
Last Quarter.
Last Quarter.
Insider Transactions
Sold Shares
Worth $14.0M over
the Last 3 Months
the Last 3 Months
Crowd Wisdom
Very Positive
Last 7 Days ▲ 2.1%
Last 30 Days ▲ 2.1%
Last 30 Days ▲ 2.1%
News Sentiment
Very Bearish
Bullish news 0%
Bearish news 100%
Bearish news 100%
Technicals
SMA
Negative
20 days / 200 days
Momentum
21.89%
12-Months-Change
Fundamentals
Return on Equity
-36.57%
Trailing 12-Months
Asset Growth
9.51%
Trailing 12-Months
Company Description
Irhythm Technologies
iRhythm Technologies, Inc., a digital healthcare company, provides ambulatory electrocardiogram (ECG) monitoring products for patients at risk for arrhythmias in the United States. It offers Zio service, an ambulatory cardiac monitoring solution that combines a wire-free, patch-based, and wearable biosensor with a cloud-based data analytic platform to help physicians to monitor patients and diagnose arrhythmias. The company's Zio XT and AT monitors, a single-use, wire-free, and wearable patch-based biosensors, records patient's heartbeats and ECG data. It has a development collaboration agreement with Verily Life Sciences LLC to develop various next-generation atrial fibrillation screening, detection, or monitoring products. The company was incorporated in 2006 and is headquartered in San Francisco, California.
IRTC Company Deck
IRTC Earnings Call
Q4 2026
0:00 / 0:00
Earnings Call Sentiment|Positive
The call emphasized strong, volume‑led revenue growth (Q4 +27.1%; FY +26.2%), meaningful margin expansion and several historic profitability and free‑cash‑flow milestones, alongside clear execution on EHR integrations, primary care adoption and AI pilots. Offsetting risks include a delay to next‑gen MCT driven by FDA and gateway changes, ongoing operating expense investments and regulatory/reimbursement uncertainties. Innovative and international channels are early stage and were conservatively treated in guidance. On balance, the company demonstrated durable core growth, expanding profitability and substantial financial flexibility while acknowledging a few timing and execution risks.View all IRTC earnings summariesIRTC Stock 12 Month Forecast
Average Price Target
$213.00
▲(72.34% Upside)
Technical Analysis
Ownership Overview
Currently, No data available
---